The present invention relates to solid preparations and combinations of pioglitazone and glimepiride and a method for their preparation. The method comprises granulating pioglitazone and glimepiride with other excipients individually and blending the both granulates to obtain solid oral dosage forms with improved stability and dissolution profile.

PROBLEM TO BE SOLVED: To provide a tablet containing glimepiride as an effective ingredient having good disintegrability in the oral cavity while retaining tablet hardness required for pharmaceutical preparation and excellent in usability and preservability. SOLUTION: This orally-disintegrating tablet is produced by mixing glimepiride of effective ingredient an extender such as water-soluble sugars sodium carboxymethyl starch crystalline cellulose a binder such as povidone and pigment in compos...

PURPOSE: A combination kit containing pinitol and a drug for preventing or treating diabetes is provided to reduce side effects and to quickly treat diabetes. CONSTITUTION: A combination kit of a component for preventing or treating diabetes contains pinitol as a first ingredient and a drug of biguanide meglitinide or sulfonylurea as a second ingredient. The biguanide is metformin. The meglitinide is repaplinide or nateglinide. The sulfonylurea is carbutamide acetohexamide chlorpropamide tolbuta...

595024 Disclosed herein is a compound which is NN-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)carbomoyl-4-yloxy)pyrimidine-2-carboxamide a pharmaceutical composition comprising it and a pharmaceutical composition further comprising an anti-obesity agent and an anti-diabetic agent. Wherein said anti-obesity agent is selected from the group consisting of dirlotapide mitratapide implitapide lorcaserin cetilistat PYY3-36 naltrexone oleoyl-estrone obinepitide pramlintide tesofensine leptin liraglut...

The invention relates to two novel metformin-based compounds obtained using the antidiabetic agent glimepiride as a contra-ion in one case and using the antidiabetic agent pioglitazone as a contra-ion in the other case. The resulting spectroscopy as well as an evaluation of the physicochemical properties thereof indicate that in the solid state both compounds correspond to ionic co-crystals attracted by ionic forces and interactions of the hydrogen bond type. The physicochemical properties of th...

The invention relates to two novel metformin-based compounds obtained using the antidiabetic agent glimepiride as a contra-ion in one case and using the antidiabetic agent pioglitazone as a contra-ion in the other case. The resulting spectroscopy as well as an evaluation of the physicochemical properties thereof indicate that in the solid state both compounds correspond to ionic co-crystals attracted by ionic forces and interactions of the hydrogen bond type. The physicochemical properties of th...